Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASBPNASDAQ:GLTONASDAQ:HOTHNASDAQ:MTEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$0.29-8.8%$0.00$0.22▼$15.80$14.36M0.9137.73 million shs649,480 shsGLTOGalecto$3.32-0.4%$2.97$2.01▼$16.07$4.38M1.3285,199 shs6,685 shsHOTHHoth Therapeutics$1.21-9.7%$0.98$0.58▼$3.80$15.98M0.553.71 million shs966,126 shsMTEXMannatech$9.80+11.4%$10.10$6.75▼$16.49$18.62M0.924,514 shs7,646 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma0.00%-20.66%+28,999,900.00%+28,999,900.00%+28,999,900.00%GLTOGalecto0.00%-1.01%+9.84%-50.51%-73.34%HOTHHoth Therapeutics0.00%-6.92%+41.69%+13.08%+30.95%MTEXMannatech0.00%+4.19%-0.51%+1.87%+43.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASBPAspire BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AGLTOGalecto1.9357 of 5 stars3.52.00.00.00.60.81.3HOTHHoth Therapeutics2.8262 of 5 stars3.65.00.00.02.20.00.6MTEXMannatech1.384 of 5 stars0.05.00.00.03.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASBPAspire Biopharma 0.00N/AN/AN/AGLTOGalecto 3.00Buy$10.00201.57% UpsideHOTHHoth Therapeutics 3.25Buy$4.00230.58% UpsideMTEXMannatech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GLTO, ASBP, MTEX, and HOTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/15/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/31/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASBPAspire BiopharmaN/AN/AN/AN/A($2.17) per shareN/AGLTOGalectoN/AN/AN/AN/A$10.99 per shareN/AHOTHHoth TherapeuticsN/AN/AN/AN/A$0.86 per shareN/AMTEXMannatech$117.87M0.16$2.14 per share4.59$4.57 per share2.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASBPAspire Biopharma-$12.54MN/A0.00∞N/AN/AN/A-508.70%N/AGLTOGalecto-$21.44M-$15.53N/AN/AN/AN/A-98.27%-84.29%8/11/2025 (Estimated)HOTHHoth Therapeutics-$8.19M-$1.14N/AN/AN/AN/A-109.18%-100.22%8/8/2025 (Estimated)MTEXMannatech$2.49M-$0.10N/A∞N/A-0.19%-2.56%-0.57%8/12/2025 (Estimated)Latest GLTO, ASBP, MTEX, and HOTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MTEXMannatechN/A-$0.80N/A-$0.80N/A$26.56 million5/12/2025Q1 2025HOTHHoth Therapeutics-$0.34-$0.27+$0.07-$0.27N/AN/A5/8/2025Q1 2025GLTOGalectoN/A-$1.92N/A-$1.92N/AN/A3/27/2025Q4 2024HOTHHoth Therapeutics-$0.39-$0.32+$0.07-$0.32N/AN/A3/26/2025Q4 2024MTEXMannatechN/A$1.20N/A$1.20N/A$29.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASBPAspire BiopharmaN/AN/AN/AN/AN/AGLTOGalectoN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/AMTEXMannatechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASBPAspire BiopharmaN/A0.220.22GLTOGalectoN/A9.629.62HOTHHoth TherapeuticsN/A15.0915.08MTEXMannatech0.461.180.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASBPAspire Biopharma19.17%GLTOGalecto14.20%HOTHHoth Therapeutics7.08%MTEXMannatech12.98%Insider OwnershipCompanyInsider OwnershipASBPAspire Biopharma48.00%GLTOGalecto10.80%HOTHHoth Therapeutics6.92%MTEXMannatech41.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASBPAspire BiopharmaN/A49.53 million25.75 millionN/AGLTOGalecto401.32 million1.18 millionOptionableHOTHHoth Therapeutics413.21 million12.30 millionNot OptionableMTEXMannatech2501.90 million1.11 millionNot OptionableGLTO, ASBP, MTEX, and HOTH HeadlinesRecent News About These CompaniesMannatech Announces Results of Annual Shareholders’ MeetingJune 5, 2025 | finance.yahoo.comMannatech Announces Results of Annual Shareholders' MeetingJune 5, 2025 | businesswire.comMannatech Premieres Powerful New Documentary on Marathon Legend Steve EdwardsMay 21, 2025 | businesswire.comMannatech Reports Financial Results for First Quarter 2025May 13, 2025 | businesswire.comAstronova outlines fiscal 2026 growth targets driven by aerospace and PI segment advancementsApril 14, 2025 | msn.comMannatech Reports Fourth Quarter 2024 Financial ResultsMarch 26, 2025 | businesswire.comMannatech Stock Soars to 52-Week High, Hits $16 MarkJanuary 30, 2025 | msn.comMannatech names Robert Toth vice chairman of the boardNovember 27, 2024 | markets.businessinsider.comMannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of DirectorsNovember 26, 2024 | businesswire.comMannatech Inc. Q3 Earnings SummaryNovember 13, 2024 | markets.businessinsider.comMannatech Reports Financial Results for Third Quarter 2024November 12, 2024 | businesswire.comTrading (MTEX) With Integrated Risk ControlsOctober 17, 2024 | news.stocktradersdaily.com(MTEX) Investment AnalysisOctober 6, 2024 | news.stocktradersdaily.comMannatech, Incorporated (NASDAQ:MTEX) Director Sells $126,232.00 in StockSeptember 12, 2024 | insidertrades.comDirector Tyler Rameson Acquires 16,288 Shares of Mannatech Inc (MTEX)September 11, 2024 | finance.yahoo.com(MTEX) Trading SignalsAugust 19, 2024 | news.stocktradersdaily.comMannatech Reports Financial Results for Second Quarter 2024August 13, 2024 | finance.yahoo.comHow To Trade (MTEX)July 29, 2024 | news.stocktradersdaily.com(MTEX) Long Term Investment AnalysisJuly 19, 2024 | news.stocktradersdaily.comMTEX Stock Earnings: Mannatech Reported Results for Q1 2024May 15, 2024 | investorplace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLTO, ASBP, MTEX, and HOTH Company DescriptionsAspire Biopharma NASDAQ:ASBP$0.29 -0.03 (-8.78%) As of 06/20/2025 04:00 PM EasternAspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.Galecto NASDAQ:GLTO$3.32 -0.01 (-0.42%) Closing price 06/20/2025 03:50 PM EasternExtended Trading$3.36 +0.04 (+1.18%) As of 06/20/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Hoth Therapeutics NASDAQ:HOTH$1.21 -0.13 (-9.70%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.20 -0.01 (-1.24%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Mannatech NASDAQ:MTEX$9.80 +1.00 (+11.36%) Closing price 06/20/2025 03:49 PM EasternExtended Trading$9.22 -0.58 (-5.92%) As of 06/20/2025 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
